Eli Lilly & Co.

LLYNYSE • USD
ThemeBiotech - Drug Development›Metabolic & Cardiometabolic
1,148.84 USD
↘ 6.13 (0.53%)AT CLOSE (11:59 AM EDT)
1,147.63
↘ 1.21 (0.11%)
POST MARKET (AS OF 08:14 PM EDT)
Post Market
AS OF 08:14 PM EDT
1,147.63
↘ 1.21 (0.11%)
🔴Market: CLOSED

Shares of Eli Lilly & Co. (LLY) are trading at $1,148.84. LLY shows a split signal: underlying fundamentals suggest "Buy" while technical indicators indicate "Sell". This is driven by a robust Altman Z-Score, exceptional Return on Equity (81.0%) and a bullish Golden Cross on the moving averages. On the valuation front, LLY trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Jul 31, 2026.

Open?$1,148.51
High?$1,150.63
Low?$1,119.00
Prev. Close?$1,154.97
Volume?2.9M
Avg. Volume?2.8M
VWAP?$1,140.46
Rel. Volume?1.02x
Bid / Ask
Bid?$1,147.10 × 40
Ask?$1,150.50 × 40
Spread?$3.40
Midpoint?$1,148.80
Valuation & Ratios
Market Cap?1024.5B
Shares Out?941.7M
Float?848.8M
Float %?90.1%
P/E Ratio?40.53
P/B Ratio?32.84
EPS?$28.35
Dividend?0.55%
Ex-Dividend?2026-08-14
News
Profile
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Themes
Biotech - Drug Development›Metabolic & CardiometabolicHealthcare - Oncology›Targeted Therapy & Precision Oncology
Employees
50.0K
Market Cap
1024.5B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.lilly.com
Listed
1970-07-09
Address
LILLY CORPORATE CTR
INDIANAPOLIS, IN 46285
Phone: (317) 276-2000
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookBuy
Strong SellNeutralStrong Buy
F-Score?
77
Z-Score?
100
Momentum?
83
Short Sent.?
52
Piotroski F-Score?6/9Mixed
Altman Z-Score?9.25Safe
Confidence?71%Moderate
Full Fundamental Analysis →
Short InterestModerate
Short % of Float?1.21%Low
Short Interest?10.3M
Days to Cover?4.1
Free Float848.8M
Avg Daily Volume2.5M
Settlement Date2026-07-15
Financial Health
Current Ratio?1.50Adequate
Quick Ratio?1.10Adequate
Cash Ratio?0.14Low
Debt/Equity?1.39Moderate
ValuationRICHLY VALUEDvs 10 peers + S&P 500
Score
33/100
P/E?
Peers
20
S&P
18
40.5PRICEY▾
P/B?
Peers
10
S&P
3
32.84HIGH▾
P/S?
Peers
20
S&P
3
14.18HIGH▾
P/FCF?
Peers
10
S&P
3
86.7PRICEY▾
EV/EBITDA?
Peers
20
S&P
10
29.3HIGH▾
EV/Sales?
Peers
20
S&P
3
14.71HIGH▾
Returns & Efficiency
ROE?
Peers
78
S&P
97
81.0%STRONG▾
ROA?
Peers
90
S&P
97
21.7%STRONG▾
Cash Flow & Enterprise
FCF?$11.8B
Enterprise Value?$1062.6B
Fundamentals ratios updated end of day
MarketsMoversWatchlist